The Merlin test (CP-GEP) stratifies melanoma patients based on risk for sentinel lymph node (SLN) metastasis, offering a powerful tool for risk-based decision-making.
Melanoma News
Fianlimab Combo Shows Activity in Advanced Melanoma Subtypes
The safety profile of fianlimab/cemiplimab in a phase 1 trial was consistent with prior reports of cemiplimab monotherapy.
PRAME-Targeted Agent Shows Activity in Pretreated Metastatic Melanoma
Phase 1b findings may affirm the therapeutic potential of IMA203 for patients with previously treated metastatic melanoma.
Scientists Use CRISPR Tools to Safely Disable Gene Mutation Linked to Advanced Skin
In a potential advance for melanoma patients, researchers at ChristianaCare’s Gene Editing Institute have used CRISPR gene editing tools to disable a gene mutation often seen in aggressive forms of this dangerous skin cancer that renders promising treatments ineffective.